Lipid Biology and Membrane Dynamics

Introduction to Lipid Biology

Lipids are a structurally diverse class of hydrophobic or amphipathic small molecules—including fatty acids, glycerophospholipids, sphingolipids, sterols, and neutral lipids—with essential roles in membrane structure, energy storage, and cellular signalling. The human lipidome contains over 100,000 distinct lipid species; advances in lipidomics using high-resolution mass spectrometry have revealed that lipid composition is precisely regulated across cell types, subcellular compartments, and physiological states. Dysregulation of lipid metabolism underlies major diseases: atherosclerosis (cholesterol), NAFLD (triglycerides in hepatocytes), type 2 diabetes (excess circulating fatty acids impairing insulin signalling), Niemann-Pick and Gaucher diseases (sphingolipid storage), and cancer (altered lipid synthesis supporting membrane biosynthesis for rapid proliferation).

Robert Hooke, Christian de Duve, and Roger Kornberg's work on cell membranes and chromosomal/membrane structure laid foundations for modern lipid biology; Peter Agre and Roderick MacKinnon's Nobel Prize work on aquaporins and ion channel structure relied on understanding of membrane lipid bilayer properties. The fluid mosaic model (Singer and Nicolson, 1972)—describing membranes as a two-dimensional fluid with mobile proteins and lipids of distinct physical properties—has been refined to incorporate lipid rafts, caveolae, and the lipid asymmetry between membrane leaflets maintained by flippases and maintained by polarised lipid synthesis and degradation.

Membrane Lipid Architecture

Glycerophospholipids

Glycerophospholipids are the most abundant membrane lipids in eukaryotic cells—glycerol backbone with two fatty acid chains esterified at sn-1 and sn-2 positions, and a polar head group at sn-3 via phosphodiester bond. Major classes: phosphatidylcholine (PC, outer leaflet, abundant), phosphatidylethanolamine (PE, inner leaflet, cone-shaped promoting membrane curvature), phosphatidylserine (PS, exclusively inner leaflet maintained by flippase ATP8A1/B1), phosphatidylinositol (PI, inner leaflet, precursor of PI-phosphates signalling lipids). Lipid asymmetry is essential: exposed PS triggers apoptosis recognition; loss of asymmetry in platelet activation enables coagulation cascade assembly. Acyl chain composition (saturated 16:0, 18:0 vs. unsaturated 18:1, 20:4, 22:6) determines biophysical properties—membrane fluidity, thickness, curvature, and protein interaction.

Sphingolipids and Lipid Rafts

Sphingolipids are generated from sphinganine/ceramide rather than glycerol. Ceramide (central sphingolipid) is a bifunctional lipid with signalling functions including apoptosis induction, autophagy, and cell senescence induction. Sphingomyelin (SM, phosphocholine head group on ceramide) and glycosphingolipids (GSLs—glucosylceramide, galactosylceramide, gangliosides) are major outer leaflet lipids. SM's tightly packed saturated acyl chains preferentially associate with cholesterol forming liquid-ordered domains (lipid rafts) distinct from the surrounding liquid-disordered bilayer. Lipid rafts concentrate GPI-anchored proteins, Src family kinases, G protein-coupled receptors, and pathogens exploiting raft-mediated endocytosis. Raft disruption by cholesterol depletion affects receptor clustering, mast cell activation, T cell signalling, and viral entry.

Lipid Signalling

Phosphoinositide Signalling

Phosphatidylinositol 4,5-bisphosphate (PIP2) at the inner plasma membrane is cleaved by PLCbeta/gamma to diacylglycerol (DAG) and IP3. IP3 binds IP3R on ER releasing Ca2+; DAG activates PKC. PI3-kinase phosphorylates PIP2 to PIP3 at the inner leaflet; PIP3 recruits Akt (via PH domain) enabling mTORC1/FOXO signalling representing the major PI3K/Akt/mTOR growth and survival cascade. PTEN phosphatase degrades PIP3—PTEN loss (common in multiple cancers) constitutively activates PI3K/Akt. Different PI3K isoforms (PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta) have different tissue expressions and functions enabling isoform-selective inhibition in cancer (idelalisib targeting PI3Kdelta in haematological malignancies) and inflammation (PI3Kgamma in innate immunity).

Eicosanoid Biosynthesis

Eicosanoids—lipid mediators derived from 20-carbon polyunsaturated fatty acids (PUFA), primarily arachidonic acid (AA, 20:4n6)—are potent local hormones mediating inflammation, pain, fever, and cardiovascular function. AA liberated from membrane phospholipids by cPLA2 is metabolised by three enzymatic pathways: COX (prostaglandins, thromboxanes), 5-LOX (leukotrienes—LTC4/D4 in asthma, anaphylaxis), and cytochrome P450 (epoxyeicosatrienoic acids EETs). NSAIDs inhibit COX-1+2 (aspirin, ibuprofen); COX-2 selective inhibitors (celecoxib) reduce GI side effects but increase cardiovascular risk through prostacyclin/thromboxane imbalance. Omega-3 PUFAs (EPA, DHA) compete with AA as eicosanoid precursors producing less pro-inflammatory series-3/5 prostanoids and resolvins/protectins actively resolving inflammation.

Lipid Droplets and Neutral Lipid Storage

Lipid droplets (LDs) were once considered inert fat globules; they are now recognised as dynamic organelles with a neutral lipid core (triacylglycerol, cholesterol esters) bounded by a phospholipid monolayer studded with LD-resident proteins (perilipins, ATGL, CGI-58, PLIN family). LD formation from ER-embedded neutral lipid lens structures under LD biogenesis proteins including seipin (FLD1 in yeast). LDs are major cellular energy reserves, hubs for lipid metabolic trafficking, and critical for diverse cellular processes including lipid signalling, VLDL assembly in hepatocytes, steroid hormone synthesis in adrenocortical cells, and immune cells. Lipophagy (selective autophagy of LDs) degrades stored triglycerides under nutrient deprivation. Lipid droplet accumulation in hepatocytes defines hepatic steatosis in NAFLD/NASH.

Examples and Applications

Example 1: Statin Mechanisms and LDL Biology

Atherosclerosis is driven by oxidised LDL accumulation in arterial intima. LDL (low-density lipid particle containing apoB-100 and ~1500 cholesterol ester molecules) is produced from VLDL in circulation through lipoprotein lipase activity; LDL receptor (LDLR) on hepatocytes internalises LDL for cellular cholesterol. Statins (HMG-CoA reductase inhibitors) reduce hepatocyte cholesterol synthesis by blocking mevalonate pathway; reduced cellular cholesterol upregulates LDLR (through SREBP2 transcription factor nuclear translocation) increasing plasma LDL clearance. Proprotein convertase subtilisin/kexin type 9 (PCSK9) degrades LDLRs—PCSK9 inhibitors (evolocumab, alirocumab) discovered from families with natural PCSK9 mutations causing very low LDL, reduce LDL 60% beyond statins with dramatic cardiovascular event reduction.

Example 2: Ceramide in Apoptosis

Ceramide—the central hub of sphingolipid metabolism—is generated by sphingomyelinase activity in response to stress signals (TNF, radiation, oxidative stress), de novo synthesis, and sphingosine-1-phosphate (S1P) lyase activity. Ceramide activates PP2A (protein phosphatase 2A), cathepsin D, and regulates Bcl-2 family via VDAC interaction inducing mitochondria-dependent apoptosis. Ceramide-enriched membrane platforms concentrate death receptors (CD95/FasL, DR5/TRAIL) after sphingomyelinase activation enhancing receptor clustering and caspase activation. S1P (sphingosine-1-phosphate) produced by sphingosine kinase 1/2 is the pro-survival counterpart of ceramide—promoting proliferation, survival, and angiogenesis via GPCR S1PR1-5. The ceramide/S1P rheostat determines life-or-death outcomes representing a therapeutic target in cancer and ischaemic injury.

Example 3: Lipid Metabolism in Cancer

Cancer cells remodel lipid metabolism to support rapid membrane biogenesis, energy needs, and signalling. Key reprogramming includes: upregulation of FASN (fatty acid synthase)—producing 16:0 palmitate as membrane building block from glucose-derived acetyl-CoA via de novo lipogenesis; ACSS2 incorporating acetate into lipids in nutrient-limited conditions; SCD1 (stearoyl-CoA desaturase) converting saturated to monounsaturated FA to reduce ER stress from saturated lipid overload; increased cholesterol biosynthesis regulated by SREBP. FASN is overexpressed in breast, prostate, and colorectal cancers correlating with poor prognosis—validating FASN as a therapeutic target. Ferroptosis—lipid peroxidation-driven cell death specific to cancers with high lipid synthesis and low GPX4 (glutathione peroxidase 4)—represents a new cancer vulnerability exploitable therapeutically.

Example 4: Lipid Storage Diseases

Lysosomal storage diseases from sphingolipid catabolic enzyme deficiencies accumulate toxic sphingolipids in lysosomes. Gaucher disease (glucocerebrosidase GBA deficiency)—glucosylceramide accumulation in macrophages—causes hepatosplenomegaly, bone disease, and in type 3 neurological manifestations. Imiglucerase ERT and oral substrate reduction therapy (eliglustat, miglustat reducing glucosylceramide synthesis) are approved. GBA mutations are the most common Parkinson's disease genetic risk factor—accumulating glycolipids in neurons impairing autophagy and alpha-synuclein clearance. Niemann-Pick type C (NPC1/NPC2 mutations)—cholesterol transport deficiency causing cholesterol and sphingomyelin accumulation in late endosomes—causes neurodegeneration; miglustat delays neurological progression. Therapies restoring NPC1 function or reducing cholesterol load are in clinical trials.

Example 5: Omega-3 Fatty Acids and Lipid Mediators

Resolution of inflammation is an active process mediated by specialised pro-resolving mediators (SPMs)—lipoxins (from AA), resolvins (from EPA and DHA), protectins, and maresins. Charles Serhan's laboratory identified these omega-3-derived anti-inflammatory lipids, demonstrating that resolution is not merely passive cessation of pro-inflammatory signalling but active lipid-orchestrated tissue restoration. SPMs reduce neutrophil recruitment, promote macrophage phagocytosis of debris, enhance tissue repair, and limit fibrosis. Pure resolvin preparations and stable SPM analogues are in preclinical development for chronic inflammatory diseases, post-surgical tissue repair, and acute lung injury. Omega-3 dietary supplementation (fish oil EPA/DHA) and the FDA-approved icosapentaenoic acid (Vascepa, purified EPA) reduce cardiovascular events in statin-treated high-risk patients.

Example 6: Lipid Nanoparticles in Drug Delivery

Lipid nanoparticles (LNPs) are the delivery system enabling mRNA vaccines (Moderna COVID-19 mRNA-1273, Pfizer-BioNTech BNT162b2) and siRNA therapeutics (patisiran for ATTR amyloidosis). LNP composition: ionisable lipid (amine group positively charged at low pH enabling nucleic acid complexation; neutral at physiological pH reducing toxicity); phospholipid helper (DSPC); PEGylated lipid (stealth PEG prevents immune recognition and extends circulation); cholesterol (membrane stability). LNPs protect mRNA from nuclease degradation, enable cellular uptake by endocytosis leveraging apolipoprotein ApoE receptor pathways in hepatocytes, and facilitate endosomal escape through ionisable lipid-membrane fusion. Optimising LNP lipid composition for different delivery targets (liver, lung, lymph nodes, brain, muscle) requires understanding receptor biology, surface chemistry, and lipid membrane physics.

Example 7: Lipidomics Technology

Modern lipidomics uses liquid chromatography-tandem mass spectrometry (LC-MS/MS)—resolving thousands of individual lipid molecular species simultaneously by mass-to-charge ratio and characteristic fragment ions. LIPID MAPS consortium established structural nomenclature for over 40,000 lipid structures and provides comprehensive spectral libraries. Untargeted HRMS (high-resolution MS, Orbitrap or Q-TOF platform) combined with MS/MS fragmentation enables discovery of novel bioactive lipids and lipid metabolites from complex biological samples. DESI-MS (desorption electrospray ionisation) and MALDI-MS imaging map lipid distributions in tissue sections—identifying spatial lipid biomarkers of cancer, NAFLD, and atherosclerotic plaque without extraction or sectioning. Machine learning classifiers applied to lipidomic profiles distinguish disease states, predict drug responses, and discover mechanistic biomarkers.

Example 8: Cholesterol Biology and ABCA1

Reverse cholesterol transport—from peripheral tissues back to liver for excretion as bile acids—is the primary anti-atherosclerotic function of HDL. ABCA1 (ATP-binding cassette transporter A1) on macrophages and hepatocytes effluxes cellular cholesterol onto apoA-I to form nascent HDL discs. Tangier disease (ABCA1 loss-of-function mutations) causes near-absence of HDL and cholesterol accumulation in macrophages causing neuropathy and cardiovascular disease—validating HDL reverse cholesterol transport in human disease. ABCG1 and SR-B1 complete cholesterol efflux from macrophages and hepatocyte cholesterol uptake. Despite HDL's protective role in reverse cholesterol transport, Mendelian randomisation and clinical trials of HDL-raising drugs (CETP inhibitors) failed to reduce cardiovascular events, suggesting that cholesterol efflux capacity of HDL particles (not simply HDL-C concentration) is the relevant functional metric.

Try it live

Everything above runs in your browser — open Lipid Bilayer & Membrane Fluidity Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.